Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Colinz LaboratoriesBOM:531210 -2.28%64 Days Payable is 108.63 as of Dec. 2025, which is 57% above its 10-year median of 69.15. GuruFocus rates BOM:531210 with a GF Score™ of 64/100 and a GF Value™ of ₹42.35 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 925 Drug Manufacturers companies, Colinz Laboratories ranks better than 65.08% on this metric.
The historical rank and industry rank for Colinz Laboratories's Days Payable or its related term are showing as below:
BOM:531210'
s Days Payable Range Over the Past 10 Years
Min: 43.09 Med: 69.15 Max: 119.18
Current: 119.18
During the past 13 years, Colinz Laboratories's highest Days Payable was 119.18. The lowest was 43.09. And the median was 69.15.
BOM:531210's Days Payable is ranked better than 65.08% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:531210: 119.18
Colinz Laboratories's Days Payable
declined
from Dec. 2024 (134.41) to Dec. 2025 (108.63).
It may suggest that Colinz Laboratoriesaccelerated paying its suppliers.
Colinz Laboratories Days Payable Related Terms
Colinz Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Colinz Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Colinz Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Colinz Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Colinz Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Colinz Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Colinz Laboratories's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Colinz Laboratories (BOM:531210) has a Days Payable of 108.63 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Colinz Laboratories and its competitors. This is 57% above median its historical median of 69.15. Over the past decade, Colinz Laboratories' Days Payable has ranged from 43.09 to 119.18. According to the industry distribution chart, Colinz Laboratories ranks #323 out of 925 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is Colinz Laboratories' Days Payable too high?
Colinz Laboratories' current Days Payable of 108.63 is 57% above median its 10-year median of 69.15. Over the past 10 years, this metric has ranged from a low of 43.09 to a high of 119.18. The Drug Manufacturers industry median Days Payable is 90.38. Colinz Laboratories' value of 108.63 is 20.2% above this industry median. Based on the distribution chart, Colinz Laboratories ranks #323 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Colinz Laboratories has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Colinz Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Colinz Laboratories ranks #323 out of 925 companies for Days Payable. This puts Colinz Laboratories in the upper half of its industry. The industry median Days Payable is 90.38. Colinz Laboratories' value of 108.63 is 20.2% above this benchmark. Historically, Colinz Laboratories' own Days Payable has ranged from 43.09 to 119.18 over the past decade. While the company's 10-year median is 69.15 vs. the industry median of 90.38, Colinz Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Colinz Laboratories's current Days Payable of 108.63 is 20.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Colinz Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Colinz Laboratories's current Days Payable is 108.63, which is 57% above median its own 10-year median of 69.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Colinz Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Colinz Laboratories (BOM:531210) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹42.35, compared to a current price of ₹80.13 — trading 89.2% above its estimated fair value. The current Days Payable is 108.63, which is 57% above median its 10-year median of 69.15 and 20.2% above the Drug Manufacturers industry median of 90.38. Colinz Laboratories' overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Colinz Laboratories (BOM:531210), the current Days Payable is 108.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Colinz Laboratories (BOM:531210) Overvalued in 2026?
Based on GuruFocus' analysis, Colinz Laboratories stock appears to be overvalued.
The current stock price of ₹80.13 is trading 89.2% above its estimated GF Value™ of ₹42.35.
GuruFocus considers Colinz Laboratories to be Significantly Overvalued.
Key valuation signals for BOM:531210:
Days Payable: 108.63 (57% above median its 10-year median of 69.15)
GF Value™: ₹42.35 vs. price of ₹80.13 (89.2% above fair value)
Industry Position: 20.2% above the Drug Manufacturers median (#323 of 925)
No single metric tells the full story. See the BOM:531210 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Colinz Laboratories Ltd is an India-based company engaged in manufacturing and trading in Pharmaceutical formulations. It offers formulations in the products category of ayurvedic, allopathic, and nutraceuticals. The company manufactures pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, and others. It also has certain specialized products for gynecology, cardiology, gastroenterology, and others. The group derives revenue from the sale of its products in India.
64GF Score
Get the complete analysis for BOM:531210
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531210 has been successfully added to your 
